However, there are challenges associated with SCF therapy, including the risk of promoting tumorigenesis, as SCF/c-kit signaling has been implicated in the progression of certain cancers, particularly gastrointestinal stromal tumors and acute myeloid leukemia. Here, KITLG is linked to gastrointestinal stromal tumor.